铽-161用于前列腺癌PSMA靶向放射性核素治疗
该研究在体外和荷瘤小鼠中比较了161Tb-PSMA-617与177Lu-PSMA-617,161Tb-PSMA-617因转换电子和俄歇电子共发射而具有更优的吸收剂量分布。体外实验中161Tb-PSMA-617对PC-3 PIP肿瘤细胞活力和存活的抑制作用更强,小鼠治疗实验显示中位生存期随活度增加而延长。研究结论支持161Tb-PSMA-617作为mCRPC治疗的潜在更有效替代方案,并建议进一步开展临床前研究和临床转化。
要点
- 161Tb-PSMA-617与177Lu-PSMA-617在体外特性和小鼠组织分布上表现相同。
- 相同活度下161Tb-PSMA-617比177Lu-PSMA-617更显著降低PC-3 PIP细胞活力和存活。
- 161Tb-PSMA-617治疗使小鼠中位生存期呈活度依赖性延长,优于未治疗对照组。
核心结论
- 161Tb-PSMA-617在体外和体内均显示出优于177Lu-PSMA-617的结果,验证了理论剂量计算中转换电子和俄歇电子附加治疗效应的预期。
- 这些数据值得开展更多临床前研究以深入探究该概念,并为161Tb-PSMA-617未来临床转化治疗mCRPC提供基础。
研究设计与样本
- 研究使用161Tb在高达100 MBq/nmol的高比活度下标记PSMA-617,并在体外和荷瘤小鼠中测试161Tb-PSMA-617以确认与177Lu-PSMA-617相同的特性。
- 体外采用PSMA阳性PC-3 PIP肿瘤细胞,通过MTT法检测细胞活力、克隆形成实验检测存活,比较161Tb-PSMA-617与177Lu-PSMA-617的效果。
- 治疗研究使用PC-3 PIP荷瘤小鼠,进一步评估161Tb-PSMA-617的疗效。
主要发现
- 161Tb-PSMA-617与177Lu-PSMA-617在体外特性和荷瘤小鼠组织分布方面表现相同。
- 在整个研究浓度范围内,相同活度的161Tb-PSMA-617较177Lu-PSMA-617更显著降低PC-3 PIP肿瘤细胞的活力和存活。
- 161Tb-PSMA-617治疗小鼠(分别为5.0 MBq/只和10 MBq/只)导致中位生存期较未治疗对照组(19天)呈活度依赖性增加(36天 vs 65天)。
- 比较161Tb-PSMA-617与177Lu-PSMA-617疗效的治疗研究显示了161Tb优于177Lu的预期优势。
临床怎么用
- 161Tb-PSMA-617因其转换电子和俄歇电子的共发射带来更优吸收剂量分布,可能成为mCRPC患者PSMA靶向治疗的更有效替代选择。
- 目前证据来自临床前研究,尚需更多临床前深入探究和未来临床转化试验验证其安全性和疗效。
局限性
- 本研究为临床前体外和动物实验,尚未在人体中验证161Tb-PSMA-617的安全性和疗效。
- 原文未报告临床样本量、P值或置信区间等统计学细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The prostate-specific membrane antigen (PSMA) has emerged as an interesting target for radionuclide therapy of metastasized castration-resistant prostate cancer (mCRPC). The aim of this study was to investigate 161Tb (T1/2 = 6.89 days; Eβ͞av = 154 keV) in combination with PSMA-617 as a potentially more effective therapeutic alternative to 177Lu-PSMA-617, due to the abundant co-emission of conversion and Auger electrons, resulting in an improved absorbed dose profile. METHODS: 161Tb was used for the radiolabeling of PSMA-617 at high specific activities up to 100 MBq/nmol. 161Tb-PSMA-617 was tested in vitro and in tumor-bearing mice to confirm equal properties, as previously determined for 177Lu-PSMA-617. The effects of 161Tb-PSMA-617 and 177Lu-PSMA-617 on cell viability (MTT assay) and survival (clonogenic assay) were compared in vitro using PSMA-positive PC-3 PIP tumor cells. 161Tb-PSMA-617 was further investigated in therapy studies using PC-3 PIP tumor-bearing mice. RESULTS: 161Tb-PSMA-617 and 177Lu-PSMA-617 displayed equal in-vitro properties and tissue distribution profiles in tumor-bearing mice. The viability and survival of PC-3 PIP tumor cells were more reduced when exposed to 161Tb-PSMA-617 as compared to the effect obtained with the same activities of 177Lu-PSMA-617 over the whole investigated concentration range. Treatment of mice with 161Tb-PSMA-617 (5.0 MBq/mouse and 10 MBq/mouse, respectively) resulted in an activity-dependent increase of the median survival (36 vs 65 days) compared to untreated control animals (19 days). Therapy studies to compare the effects of 161Tb-PSMA-617 and 177Lu-PSMA-617 indicated the anticipated superiority of 161Tb over 177Lu. CONCLUSION: 161Tb-PSMA-617 showed superior in-vitro and in-vivo results as compared to 177Lu-PSMA-617, confirming theoretical dose calculations that indicate an additive therapeutic effect of conversion and Auger electrons in the case of 161Tb. These data warrant more preclinical research for in-depth investigations of the proposed concept, and present a basis for future clinical translation of 161Tb-PSMA-617 for the treatment of mCRPC.
引用
- Müller C, Umbricht CA, Gracheva N, et al. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. Eur J Nucl Med Mol Imaging. 2019. PMID: 31134301. doi:10.1007/s00259-019-04345-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。